Avicanna (AVCN) investor relations material

Company overview and business model

• Focuses on evidence-based, standardized cannabinoid-based products for medical and pharmaceutical use, not recreational markets.

• Operates four divisions: medical cannabis products, medical cannabis platform (MyMedi), pharmaceutical pipeline, and raw material/API division in Colombia.

• MyMedi platform offers nationwide telemedicine, patient support, insurance adjudication, and medical education in Canada.

• RHO Phyto is the flagship medical brand, offering non-inhaled, targeted cannabinoid products for specific clinical indications.

• International expansion is a key priority, leveraging Canadian proof-of-concept to enter new markets.

Research, development, and intellectual property

• Originated as a drug development company with a strong R&D focus, including preclinical and clinical development.

• Collaborates with leading academic and clinical institutions, benefiting from Canada’s regulatory environment.

• Owns several USPTO patents and has a significant number of pipeline products submitted for patent approval.

• Developed proprietary drug delivery technologies, such as nano-emulsion, now commercialized in multiple products.

• Intellectual property and clinical data are leveraged for global licensing and partnerships.

Pharmaceutical pipeline and clinical progress

• Focuses on drug candidates for sleep, rare skin diseases, pain, anxiety, depression, epilepsy, and neurological disorders.

• Trunerox, the first approved pharmaceutical, launched in Colombia for Lennox-Gastaut Syndrome.

• Conducting a phase II osteoarthritic pain trial with Toronto General Hospital/UHN, with data and IP retained.

• Pipeline includes oral and topical formulations, with expansion plans based on clinical insights.

• Plans to collaborate with larger pharma for late-stage clinical development and global commercialization.